Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.

van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, Eden S, Warkentin JV, Sterling TR
Int J Antimicrob Agents. 2013 42 (3): 232-7

PMID: 23806638 · PMCID: PMC3780576 · DOI:10.1016/j.ijantimicag.2013.04.027

Fluoroquinolone exposure before tuberculosis (TB) diagnosis is common. We anticipated that exposure to older-generation fluoroquinolones is associated with greater fluoroquinolone MICs in Mycobacterium tuberculosis than exposure to newer agents. A nested case-control study was performed among newly diagnosed TB patients reported to the Tennessee Department of Health (January 2002-December 2009). Each fluoroquinolone-resistant case (n=25) was matched to two fluoroquinolone-susceptible controls (n=50). Ciprofloxacin and ofloxacin were classified as older-generation fluoroquinolones; levofloxacin, moxifloxacin and gatifloxacin were considered newer agents. There was no difference between median ofloxacin MIC for isolates from 9 patients exposed only to older fluoroquinolones, 25 exposed only to newer fluoroquinolones, 6 exposed to both and 35 fluoroquinolone-unexposed patients (Kruskal-Wallis, P=0.35). Using multivariate proportional odds logistic regression adjusting for age and sex, duration of exposure to newer fluoroquinolones was independently associated with higher MIC (OR=1.79, 95% CI 1.22-2.64), but duration of exposure to older fluoroquinolones was not (OR=0.94, 95% CI 0.50-1.78). Isolates from patients exposed only to newer fluoroquinolones tended to have mutations at gyrA codons 90, 91 or 94 more frequently than those exposed only to older fluoroquinolones (44% vs. 11%). We were surprised to find that duration of exposure to newer fluoroquinolones, but not older ones, was independently associated with higher ofloxacin MIC. This suggests that the mutant selection window lower boundary is likely to have clinical relevance; caution is warranted when newer fluoroquinolones are prescribed to patients with TB risk factors.

Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

MeSH Terms (21)

Adult Aged Anti-Bacterial Agents Aza Compounds Case-Control Studies Ciprofloxacin DNA Gyrase Drug Resistance, Bacterial Female Fluoroquinolones Gatifloxacin Humans Levofloxacin Male Microbial Sensitivity Tests Middle Aged Moxifloxacin Mycobacterium tuberculosis Ofloxacin Quinolines Tuberculosis

Connections (1)

This publication is referenced by other Labnodes entities: